TARS Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals CEO Bobak Azamian sold 6,000 shares of the company's stock for $495,060 on December 24th, reducing his ownership by 0.69%. Following the transaction, Azamian directly owns 857,991 shares worth approximately $70.8 million. The company recently beat revenue and EPS estimates but remains unprofitable; analysts maintain a "Moderate Buy" consensus with an average target price of $79.86.

Tarsus Pharmaceuticals, Inc. announced that its CEO and Chairman, Bobak Azamian, M.D., Ph.D., and Chief Financial and Strategy Officer, Jeff Farrow, will participate in 1:1 meetings at the Bank of America 2023 Healthcare Conference on May 10, 2023. The company is advancing several investigational medicines, including TP-03 for Demodex blepharitis, TP-04 for papulopustular rosacea, and TP-05 for Lyme disease prevention. Tarsus focuses on addressing unmet medical needs with scientific and technological advancements, initially in eye care.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a loss-making biopharmaceutical company, is projected by analysts to break even and turn a profit of US$91 million in 2026, recuperating from a US$81 million trailing-twelve-month loss. The company's capital management is considered judicious, with low debt contributing to reduced investment risk despite its current unprofitable status. Investors should note the optimistic 63% annual growth rate required for this breakeven prediction, and consider further analysis of the company's fundamentals beyond this overview.

This article analyzes the future prospects of loss-making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), focusing on when the company is expected to achieve profitability. According to analyst forecasts, Tarsus Pharmaceuticals is projected to break even and turn a profit of US$91m in 2026, driven by an optimistic average annual growth rate of 63%. The company's low debt-to-equity ratio also suggests judicious capital management, reducing investment risk despite its current loss-making status.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is nearing profitability, with analysts predicting a final loss in 2025 before achieving a profit of US$91m in 2026. The company, currently with a US$3.5b market cap, needs to grow at an average annual rate of 63% to reach this breakeven target. Its judicious capital management, with debt making up only 22% of equity, reduces risk for investors despite its current loss-making status.

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals Inc, sold 7,397 shares of the company on December 16, 2025. This transaction adds to a trend of insider selling at Tarsus Pharmaceuticals, with 16 insider sells and no insider buys over the past year. The stock is currently trading at $80.1, with a price-to-GF-Value ratio of 0.5, suggesting it may be a "Possible Value Trap, Think Twice."